Search results
Results from the WOW.Com Content Network
Suzetrigine, sold under the brand name Journavx, is a medication used for the management of pain. [1] [2] It is a non-opioid, small-molecule analgesic that works as a selective inhibitor of Na v 1.8-dependent pain-signaling pathways in the peripheral nervous system, [3] [4] avoiding the addictive potential of opioids.
Filgrastim, sold under the brand name Neupogen among others, is a medication used to treat low neutrophil count. [19] Low neutrophil counts may occur with HIV/AIDS, following chemotherapy or radiation poisoning, or be of an unknown cause. [19]
This multi-page article lists pharmaceutical drugs alphabetically by name. Many drugs have more than one name and, therefore, the same drug may be listed more than once. ...
On March 6, 2015, Zarxio obtained the first approval of FDA. [15] Sandoz's Zarxio is biosimilar to Amgen's Neupogen (filgrastim), which was originally licensed in 1991. This is the first product to be passed under the Biologics Price Competition and Innovation Act of 2009 (BPCI Act), which was passed as part of the Affordable Healthcare Act.
What links here; Related changes; Upload file; Special pages; Permanent link; Page information; Cite this page; Get shortened URL; Download QR code
The U.S. Food and Drug Administration (FDA) approves the country's first biosimilar drug, Zarxio (Europe: 2009, as Zarzio), made by Novartis. Biosimilars are a relatively new class of drugs designed to pave the way for less expensive versions of the complex biologics drug class, and they are not synthesized from chemicals like other drugs, but ...
To reduce this risk, it is common to use several different drugs together that are each aimed at different targets. In addition to those non-human proteases listed above, inhibitors of human proteases may be used to treat cancer. See the articles matrix metalloproteinase inhibitor (–mastat) and proteasome inhibitor (–zomib). [1]
Sacituzumab govitecan is indicated for the treatment of adults with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease; [11] people with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease; [14] and for people ...